A biotech startup targeting transcription factors
flaretx.comLinkedInCambridge, USABiotech
LATEST ROUND
Series C
$85M · 2026-06-30
RAISED ON RECORD · USD
$290M
across 3 rounds on record
INVESTORS
15
4 leads
SOURCES
7
from 5 publishers
A biotech startup targeting transcription factors
flaretx.comLinkedInCambridge, USABiotech
5 sources
Sources agree on the Series C, $85 million amount, lead investors, and participating investors. The roundup places the item in the June 29 to July 2 week, but the company’s release fixes the announcement date at June 30, 2026.
1 source
Developing: it holds up against its sources so far, and firms up as more reporting lands.
The company’s release states the Series B amount, date, leads, and full investor syndicate. It gives “Cambridge, MA” only as the dateline, not as an explicit headquarters statement.
1 source
Developing: it holds up against its sources so far, and firms up as more reporting lands.
Sources agree on the Series A, $82 million amount, date, and syndicate. The source gives “Cambridge, Mass.” as the dateline but does not state the company's headquarters.
| Round | Amount | Announced | Lead | Buzz |
|---|---|---|---|---|
| Series C [ REPORTED LATER ]: This round was announced before Fireround first saw it. It stays in the company's history, not in Latest, Trending, or alerts. | $85M | 2026-06-30 | Third Rock Ventures, Nextech Invest | No recent discussion |
5 sources [ VERIFIED · CORRECTED ] read against 5 sources
Sources agree on the Series C, $85 million amount, lead investors, and participating investors. The roundup places the item in the June 29 to July 2 week, but the company’s release fixes the announcement date at June 30, 2026. | ||||
Flare Therapeutics develops small-molecule precision medicines that target hard-to-drug transcription factors for cancer and other diseases, initially focusing on precision oncology.
Checked against 10 sources on Sep 24
| Series B [ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $123M | 2023-03-22 | GordonMD Global Investments, Pfizer Ventures | No recent discussion |
1 source [ DEVELOPING ] Developing: it holds up against its sources so far, and firms up as more reporting lands. read against 1 source The company’s release states the Series B amount, date, leads, and full investor syndicate. It gives “Cambridge, MA” only as the dateline, not as an explicit headquarters statement. [ BUILT WITH ]·[ SEARCH ]found by Firecrawl search·[ SCRAPE ]1 page read: flaretx.com·[ JSON ]round read into a schema, with the sentence that states it·[ VERIFY ]confirmedchecked against 1 source·[ BRANDING ]logo and colour from the homepage·[ AGENT ]company research by the Firecrawl agent | ||||
| Series A [ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $82M | 2021-05-13 | Third Rock Ventures | No recent discussion |
1 source [ DEVELOPING ] Developing: it holds up against its sources so far, and firms up as more reporting lands. read against 1 source Sources agree on the Series A, $82 million amount, date, and syndicate. The source gives “Cambridge, Mass.” as the dateline but does not state the company's headquarters. [ BUILT WITH ]·[ SEARCH ]found by Firecrawl search·[ SCRAPE ]1 page read: flaretx.com·[ JSON ]round read into a schema, with the sentence that states it·[ VERIFY ]confirmedchecked against 1 source·[ BRANDING ]logo and colour from the homepage·[ AGENT ]company research by the Firecrawl agent | ||||